Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Breast Cancer

  Free Subscription


10.02.2020

1 Am J Clin Oncol
1 Am J Surg
3 Ann Surg Oncol
6 Anticancer Res
5 BMC Cancer
1 Br J Cancer
2 Breast Cancer
2 Breast Cancer (Auckl)
3 Breast Cancer Res
10 Breast Cancer Res Treat
2 Cancer
1 Cancer Lett
2 Cancer Res
4 Clin Breast Cancer
3 Clin Cancer Res
2 Eur Radiol
5 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 JAMA
1 N Engl J Med
1 NPJ Breast Cancer
2 Oncogene
3 Oncol Rep
2 PLoS One
1 Radiology
1 Science


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. WENG X, Huang X, Li H, Lin S, et al
    First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Am J Clin Oncol. 2020 Feb 5. doi: 10.1097/COC.0000000000000671.
    PubMed     Text format     Abstract available


    Am J Surg

  2. SROUR MK, Lee M, Walcott-Sapp S, Kim S, et al
    Thirty-day postoperative morbidity in patients with breast cancer following neoadjuvant chemotherapy.
    Am J Surg. 2020 Jan 22. pii: S0002-9610(20)30035.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  3. TRAN HT, Pack D, Mylander C, Martino L, et al
    Ultrasound-Based Nomogram Identifies Breast Cancer Patients Unlikely to Harbor Axillary Metastasis: Towards Selective Omission of Sentinel Lymph Node Biopsy.
    Ann Surg Oncol. 2020 Feb 5. pii: 10.1245/s10434-019-08164.
    PubMed     Text format     Abstract available

  4. LAI HW, Chen ST, Tai CM, Lin SL, et al
    Robotic- Versus Endoscopic-Assisted Nipple-Sparing Mastectomy with Immediate Prosthesis Breast Reconstruction in the Management of Breast Cancer: A Case-Control Comparison Study with Analysis of Clinical Outcomes, Learning Curve, Patient-Reported Aest
    Ann Surg Oncol. 2020 Feb 3. pii: 10.1245/s10434-020-08223.
    PubMed     Text format     Abstract available

  5. CASTELO M, Hu SY, Dossa F, Acuna SA, et al
    Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review.
    Ann Surg Oncol. 2020 Feb 4. pii: 10.1245/s10434-020-08225.
    PubMed     Text format     Abstract available


    Anticancer Res

  6. KLOPOTOWSKA D, Matuszyk J
    VDR Agonists Increase Sensitivity of MCF-7 and BT-474 Breast Cancer Cells to 5 FU.
    Anticancer Res. 2020;40:837-840.
    PubMed     Text format     Abstract available

  7. GIANI M, Renda I, Vallario A, Tavella K, et al
    Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience.
    Anticancer Res. 2020;40:1079-1085.
    PubMed     Text format     Abstract available

  8. RAD JG, Hoskin DW
    Delivery of Apoptosis-inducing Piperine to Triple-negative Breast Cancer Cells via Co-polymeric Nanoparticles.
    Anticancer Res. 2020;40:689-694.
    PubMed     Text format     Abstract available

  9. YAMASHITA H, Ishida N, Hatanaka Y, Hagio K, et al
    HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence.
    Anticancer Res. 2020;40:645-652.
    PubMed     Text format     Abstract available

  10. PHILIPOVSKIY A, Campbell A, Heydarian R, Castillo B, et al
    Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
    Anticancer Res. 2020;40:857-864.
    PubMed     Text format     Abstract available

  11. MORAIS S, Costa AR, Lopes-Conceicao L, Brandao M, et al
    Treatment and Other Healthcare Use of Breast Cancer Patients With a Previous Cancer Diagnosis.
    Anticancer Res. 2020;40:1041-1048.
    PubMed     Text format     Abstract available


    BMC Cancer

  12. ZHOU J, Lu J, Gao C, Zeng J, et al
    Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI.
    BMC Cancer. 2020;20:100.
    PubMed     Text format     Abstract available

  13. GINZAC A, Barres B, Chanchou M, Gadea E, et al
    A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
    BMC Cancer. 2020;20:96.
    PubMed     Text format     Abstract available

  14. NI-JIA-TI MY, Ai-Hai-Ti DL, Huo-Jia AS, Wu-Mai-Er PL, et al
    Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer.
    BMC Cancer. 2020;20:94.
    PubMed     Text format     Abstract available

  15. SOLIMAN H, Shah V, Srkalovic G, Mahtani R, et al
    MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
    BMC Cancer. 2020;20:81.
    PubMed     Text format     Abstract available

  16. BACOLOD MD, Huang J, Giardina SF, Feinberg PB, et al
    Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection.
    BMC Cancer. 2020;20:85.
    PubMed     Text format     Abstract available


    Br J Cancer

  17. VARIKUTI S, Singh B, Volpedo G, Ahirwar DK, et al
    Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
    Br J Cancer. 2020 Feb 6. pii: 10.1038/s41416-020-0743.
    PubMed     Text format     Abstract available


    Breast Cancer

  18. MAROUFI NF, Vahedian V, Akbarzadeh M, Mohammadian M, et al
    The apatinib inhibits breast cancer cell line MDA-MB-231 in vitro by inducing apoptosis, cell cycle arrest, and regulating nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling pathways.
    Breast Cancer. 2020 Feb 5. pii: 10.1007/s12282-020-01055.
    PubMed     Text format     Abstract available

  19. WANG B, Zhu L, He C, Tai M, et al
    Growth pattern can be used as a new characteristic to predict malignancy in breast cancer.
    Breast Cancer. 2020 Jan 3. pii: 10.1007/s12282-019-01041.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  20. VAN THUAN T, Van Chu N, Khoa PH, Quang NT, et al
    A Novel BRCA1 Gene Mutation Detected With Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A Case Report.
    Breast Cancer (Auckl). 2020;14:1178223420901555.
    PubMed     Text format     Abstract available

  21. MISHRA D, Patel V, Banerjee D
    Nitric Oxide and S-Nitrosylation in Cancers: Emphasis on Breast Cancer.
    Breast Cancer (Auckl). 2020;14:1178223419882688.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  22. DE RUIJTER TC, van der Heide F, Smits KM, Aarts MJ, et al
    Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
    Breast Cancer Res. 2020;22:13.
    PubMed     Text format     Abstract available

  23. PANCHOLI S, Leal MF, Ribas R, Simigdala N, et al
    Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
    Breast Cancer Res. 2020;22:14.
    PubMed     Text format     Abstract available

  24. ZUNDELEVICH A, Dadiani M, Kahana-Edwin S, Itay A, et al
    ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Breast Cancer Res. 2020;22:16.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  25. LI M, Xiong Y, Liao C, He Y, et al
    Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2020 Feb 1. pii: 10.1007/s10549-020-05551.
    PubMed     Text format     Abstract available

  26. SHIBAYAMA T, Low SK, Ono M, Kobayashi T, et al
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-019-05512.
    PubMed     Text format     Abstract available

  27. ZHU J, Wang F, Shi L, Cai H, et al
    Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05541.
    PubMed     Text format     Abstract available

  28. KIM HS, Yoo TK, Park WC, Chae BJ, et al
    The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05550.
    PubMed     Text format     Abstract available

  29. PAREKH VS, Jacobs MA
    Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05533.
    PubMed     Text format     Abstract available


  30. UK Interdisciplinary Breast Cancer Symposium 2020.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-019-05514.
    PubMed     Text format    

  31. JOOB B, Wiwanitkit V
    CYP24A1 polymorphisms and breast cancer risk.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05553.
    PubMed     Text format    

  32. GUO S, Zhang C, Mottamal M, Hossain A, et al
    GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05558.
    PubMed     Text format     Abstract available

  33. MILLS MN, Figura NB, Arrington JA, Yu HM, et al
    Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05552.
    PubMed     Text format     Abstract available

  34. DICORPO D, Tiwari A, Tang R, Griffin M, et al
    The role of Micro-CT in imaging breast cancer specimens.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05547.
    PubMed     Text format     Abstract available


    Cancer

  35. XU Z, Tian S, Kong LQ
    On the proportion of male breast cancer among all breast cancers.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32731.
    PubMed     Text format    

  36. YADAV S, Karam D, Bin Riaz I, Xie H, et al
    Reply to On the proportion of male breast cancer among all breast cancers.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32727.
    PubMed     Text format    


    Cancer Lett

  37. DING J, Yao Y, Huang G, Wang X, et al
    Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30046.
    PubMed     Text format     Abstract available


    Cancer Res

  38. HEBERT JD, Myers SA, Naba A, Abbruzzese G, et al
    Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches.
    Cancer Res. 2020 Feb 4. pii: 0008-5472.CAN-19-2961.
    PubMed     Text format     Abstract available

  39. MALLETER M, Tauzin S, Bessede A, Castellano R, et al
    Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer.
    Cancer Res. 2020;80:639.
    PubMed     Text format    


    Clin Breast Cancer

  40. KITTANEH M, Badve S, Caldera H, Coleman R, et al
    Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
    Clin Breast Cancer. 2020 Jan 8. pii: S1526-8209(20)30004.
    PubMed     Text format     Abstract available

  41. RASHAD N, Abdelhamid T, Shouman SA, Nassar H, et al
    Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
    Clin Breast Cancer. 2020 Jan 7. pii: S1526-8209(20)30002.
    PubMed     Text format     Abstract available

  42. ITANI N, Grogan N, Mott S, Phadke S, et al
    Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival.
    Clin Breast Cancer. 2019 Nov 21. pii: S1526-8209(19)30735.
    PubMed     Text format     Abstract available

  43. FARD ZT
    The Relationship Between eNOS Polymorphisms With Age, Smoking, Body Mass Index, and Clinicopathologic Parameters in Patients With Breast Cancer in Comparison With a Control Group.
    Clin Breast Cancer. 2020 Jan 7. pii: S1526-8209(20)30003.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  44. BLAES AH, Domingo-Musibay E, Kalinsky K
    Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
    Clin Cancer Res. 2020 Feb 6. pii: 1078-0432.CCR-19-3818.
    PubMed     Text format     Abstract available

  45. BARROSO-SOUSA R, Keenan TE, Pernas S, Exman P, et al
    Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer.
    Clin Cancer Res. 2020 Feb 4. pii: 1078-0432.CCR-19-3507.
    PubMed     Text format     Abstract available

  46. ASLEH K, Brauer HA, Sullivan A, Lauttia S, et al
    Predictive biomarkers for adjuvant capecitabine benefit in early stage triple negative breast cancer in the FinXX clinical trial.
    Clin Cancer Res. 2020 Jan 31. pii: 1078-0432.CCR-19-1945.
    PubMed     Text format     Abstract available


    Eur Radiol

  47. LEE SE, Lee JH, Han K, Kim EK, et al
    BI-RADS category 3, 4, and 5 lesions identified at preoperative breast MRI in patients with breast cancer: implications for management.
    Eur Radiol. 2020 Jan 31. pii: 10.1007/s00330-019-06620.
    PubMed     Text format     Abstract available

  48. MOON JI, Choi BH, Baek HJ, Ryu KH, et al
    Comprehensive analyses with radiological and biological markers of breast cancer on contrast-enhanced chest CT: a single center experience using dual-layer spectral detector CT.
    Eur Radiol. 2020 Feb 5. pii: 10.1007/s00330-019-06615.
    PubMed     Text format     Abstract available


    Int J Cancer

  49. SCHOEMAKER MJ, Nichols HB, Wright LB, Brook MN, et al
    Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32892.
    PubMed     Text format     Abstract available

  50. XIAO Q, Zhou Y, Winter S, Buttner F, et al
    Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32898.
    PubMed     Text format     Abstract available

  51. HENSON KE, McGale P, Darby SC, Parkin DM, et al
    Cardiac Mortality after Radiotherapy, Chemotherapy and Endocrine Therapy for Breast Cancer: Cohort Study of 2 Million Women from 57 Cancer Registries in 22 Countries.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32908.
    PubMed     Text format     Abstract available

  52. ZENG, Liang YK, Xiao YS, Wei XL, et al
    Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct down-regulation of MCAM in triple-negative breast cancer cells.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32911.
    PubMed     Text format     Abstract available

  53. CHANG VC, Cotterchio M, Bondy SJ, Kotsopoulos J, et al
    Iron intake, oxidative stress-related genes, and breast cancer risk.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32906.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  54. KIROVA YM, Loap P, Fourquet A
    Benefit of Post Mastectomy Radiation Therapy (PMRT) in Node-Positive, HER2-Positive Patients With Breast Cancer Receiving Anti-HER2 Treatments.
    Int J Radiat Oncol Biol Phys. 2020;106:511-513.
    PubMed     Text format    

  55. LEE E, Eum SY, Slifer SH, Martin ER, et al
    Association Between Polymorphisms in DNA Damage Repair Genes and Radiation Therapy-Induced Early Adverse Skin Reactions in a Breast Cancer Population: A Polygenic Risk Score Approach.
    Int J Radiat Oncol Biol Phys. 2020 Jan 29. pii: S0360-3016(19)34539.
    PubMed     Text format     Abstract available


    J Clin Oncol

  56. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Pan K, et al
    Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial.
    J Clin Oncol. 2020 Feb 7:JCO1900435. doi: 10.1200/JCO.19.00435.
    PubMed     Text format     Abstract available


    JAMA

  57. VOELKER R
    Another Targeted Therapy for ERBB2-Positive Breast Cancer.
    JAMA. 2020;323:408.
    PubMed     Text format    


    N Engl J Med

  58. PINKERTON JV
    Hormone Therapy for Postmenopausal Women.
    N Engl J Med. 2020;382:446-455.
    PubMed     Text format    


    NPJ Breast Cancer

  59. FACKLER MJ, Cho S, Cope L, Gabrielson E, et al
    DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.
    NPJ Breast Cancer. 2020;6:3.
    PubMed     Text format     Abstract available


    Oncogene

  60. RAN R, Harrison H, Syamimi Ariffin N, Ayub R, et al
    A role for CBFbeta in maintaining the metastatic phenotype of breast cancer cells.
    Oncogene. 2020 Jan 31. pii: 10.1038/s41388-020-1170.
    PubMed     Text format     Abstract available

  61. TARULLO SE, Hill RC, Hansen KC, Behbod F, et al
    Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival.
    Oncogene. 2020 Feb 4. pii: 10.1038/s41388-020-1192.
    PubMed     Text format     Abstract available


    Oncol Rep

  62. LI C, Wang A, Chen Y, Liu Y, et al
    MicroRNA2995p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39.
    Oncol Rep. 2020 Jan 31. doi: 10.3892/or.2020.7486.
    PubMed     Text format     Abstract available

  63. AL-YOUSEF N, Shinwari Z, Al-Shahrani B, Al-Showimi M, et al
    Curcumin induces reexpression of BRCA1 and suppression of gamma synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Oncol Rep. 2020 Jan 20. doi: 10.3892/or.2020.7473.
    PubMed     Text format     Abstract available

  64. ZHANG Z, Li Z, Deng M, Liu B, et al
    Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer.
    Oncol Rep. 2020 Jan 17. doi: 10.3892/or.2020.7471.
    PubMed     Text format     Abstract available


    PLoS One

  65. ROJAS L, Muniz S, Medina L, Pena J, et al
    Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
    PLoS One. 2020;15:e0227961.
    PubMed     Text format     Abstract available

  66. FERREIRA LC, Orso F, Dettori D, Lacerda JZ, et al
    The role of melatonin on miRNAs modulation in triple-negative breast cancer cells.
    PLoS One. 2020;15:e0228062.
    PubMed     Text format     Abstract available


    Radiology

  67. PARK AY, Han MR, Park KH, Kim JS, et al
    Radiogenomic Analysis of Breast Cancer by Using B-Mode and Vascular US and RNA Sequencing.
    Radiology. 2020 Feb 4:191368. doi: 10.1148/radiol.2020191368.
    PubMed     Text format     Abstract available


    Science

  68. EBRIGHT RY, Lee S, Wittner BS, Niederhoffer KL, et al
    Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis.
    Science. 2020 Feb 6. pii: science.aay0939. doi: 10.1126/science.aay0939.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: